A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTI-CENTER, OPEN-LABEL, CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CELLULAR IMMUNOTHERAPY WITH MDR-101 FOR INDUCTION OF IMMUNE TOLERANCE IN RECIPIENTS OF HLA-MATCHED, LIVING DONOR KIDNEY TRANSPLANTS
- Registry ID
- MDR-101-MLK
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- MEDEOR THERAPEUTICS, INC.
- Start date
- 2019-11-27
- Last update
- 2018-11-15
Conditions
Related clinical trials
- A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, RANDOMIZED PHASE 2 TRIAL EVALUATING THE EFFICACY AND SAFETY OF FELZARTAMAB IN RECIPIENTS OF KIDNEY TRANSPLANTS WITH LATE ISOLATED MICROVASCULAR INFLAMMATION (MVI) - (TRANSPIRE0
- A PHASE 2B, NON-RANDOMIZED, CONTROLLED, OPEN-LABEL, EXTENSION STUDY TO EVALUATE
THE PERSISTENCE OF IMMUNE RESPONSE OF THE ADJUVANTED RSVPREF3 VACCINE AND THE
SAFETY AND IMMUNOGENICITY FOLLOWING REVACCINATION IN LUNG AND KIDNEY TRANSPLANT
RECIPIENTS (¿18 YEARS OF AGE)
- SEMAGLUTIDE FOR THE PREVENTION OF POST-TRANSPLANT DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF RAVULIZUMAB ADMINISTERED INTRAVENOUSLY IN
ADULT PARTICIPANTS AT HIGH RISK OF DELAYED GRAFT FUNCTION AFTER KIDNEY
TRANSPLANTATION
- EVALUATION OF THIOSULFATE IN END STAGE RENAL DISEASE AND KIDNEY
TRANSPLANTATION
- A PHASE 2B, RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY TO
EVALUATE THE IMMUNE RESPONSE AND SAFETY OF THE RSVPREF3 OA INVESTIGATIONAL VACCINE IN
ADULTS (¿50 YEARS OF AGE) WHEN ADMINISTERED TO LUNG AND RENAL TRANSPLANT RECIPIENTS
COMPARING 1 VERSUS 2 DOSES AND COMPARED TO HEALTHY CONTROLS (¿50 YEARS OF AGE)
RECEIVING 1 DOSE
View on source registry